ES2946510T3 - Composiciones formadoras de espuma y métodos para suministrar un agente activo a una cavidad corporal - Google Patents
Composiciones formadoras de espuma y métodos para suministrar un agente activo a una cavidad corporal Download PDFInfo
- Publication number
- ES2946510T3 ES2946510T3 ES15843723T ES15843723T ES2946510T3 ES 2946510 T3 ES2946510 T3 ES 2946510T3 ES 15843723 T ES15843723 T ES 15843723T ES 15843723 T ES15843723 T ES 15843723T ES 2946510 T3 ES2946510 T3 ES 2946510T3
- Authority
- ES
- Spain
- Prior art keywords
- foam
- body cavity
- forming composition
- composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 135
- 239000013543 active substance Substances 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title abstract description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 166
- 239000006260 foam Substances 0.000 claims abstract description 145
- 239000013078 crystal Substances 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 150000002632 lipids Chemical class 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 37
- 239000007787 solid Substances 0.000 claims description 32
- 239000003380 propellant Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000002844 melting Methods 0.000 claims description 21
- 230000008018 melting Effects 0.000 claims description 21
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 14
- -1 isopropane Chemical compound 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 8
- 239000001273 butane Substances 0.000 claims description 7
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 7
- 239000001294 propane Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000005141 Otitis Diseases 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 239000002249 anxiolytic agent Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 208000019258 ear infection Diseases 0.000 claims description 3
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001282 iso-butane Substances 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 51
- 239000002253 acid Substances 0.000 abstract description 16
- 239000004604 Blowing Agent Substances 0.000 abstract description 11
- 230000036760 body temperature Effects 0.000 abstract description 11
- 239000000872 buffer Substances 0.000 abstract description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- 102000016938 Catalase Human genes 0.000 description 24
- 108010053835 Catalase Proteins 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 238000012384 transportation and delivery Methods 0.000 description 19
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 239000007789 gas Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000003381 stabilizer Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 210000001215 vagina Anatomy 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 7
- 206010046914 Vaginal infection Diseases 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 150000002978 peroxides Chemical class 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010018612 Gonorrhoea Diseases 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 238000006701 autoxidation reaction Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 208000001786 gonorrhea Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000207201 Gardnerella vaginalis Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960002677 darifenacin Drugs 0.000 description 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- TVQLLNFANZSCGY-UHFFFAOYSA-N disodium;dioxido(oxo)tin Chemical compound [Na+].[Na+].[O-][Sn]([O-])=O TVQLLNFANZSCGY-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960002978 fesoterodine Drugs 0.000 description 2
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940120393 myrbetriq Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960005434 oxybutynin Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229940048084 pyrophosphate Drugs 0.000 description 2
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 229940079864 sodium stannate Drugs 0.000 description 2
- 229960003855 solifenacin Drugs 0.000 description 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960004045 tolterodine Drugs 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- 229960001491 trospium Drugs 0.000 description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 2
- WTXXSZUATXIAJO-OWBHPGMISA-N (Z)-14-methylpentadec-2-enoic acid Chemical compound CC(CCCCCCCCCC\C=C/C(=O)O)C WTXXSZUATXIAJO-OWBHPGMISA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940037157 anticorticosteroids Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008752 local inflammatory process Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055001P | 2014-09-25 | 2014-09-25 | |
| PCT/SE2015/051011 WO2016048230A1 (en) | 2014-09-25 | 2015-09-25 | Foam-forming compositions and methods for delivering an active agent to a body cavity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2946510T3 true ES2946510T3 (es) | 2023-07-20 |
Family
ID=55581573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15843723T Active ES2946510T3 (es) | 2014-09-25 | 2015-09-25 | Composiciones formadoras de espuma y métodos para suministrar un agente activo a una cavidad corporal |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9895311B2 (enExample) |
| EP (2) | EP4218803A3 (enExample) |
| JP (1) | JP6659674B2 (enExample) |
| KR (1) | KR102569954B1 (enExample) |
| CN (1) | CN106687109B (enExample) |
| AU (1) | AU2015322112B2 (enExample) |
| BR (1) | BR112017006154B1 (enExample) |
| CA (1) | CA2959717C (enExample) |
| DK (1) | DK3197431T3 (enExample) |
| ES (1) | ES2946510T3 (enExample) |
| FI (1) | FI3197431T3 (enExample) |
| HU (1) | HUE062224T2 (enExample) |
| PL (1) | PL3197431T3 (enExample) |
| PT (1) | PT3197431T (enExample) |
| RU (1) | RU2710019C2 (enExample) |
| WO (1) | WO2016048230A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895311B2 (en) * | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
| US20200069630A1 (en) * | 2016-07-11 | 2020-03-05 | Hennipen Life Sciences, Llc | Compositions for sexually transmitted diseases |
| FI3628002T3 (fi) * | 2017-05-23 | 2023-05-15 | Pharmiva Ab | Vaahtoa muodostavat koostumukset aktiivisen aineen kuljettamiseksi kehon onteloon |
| KR20240036492A (ko) | 2021-01-27 | 2024-03-20 | 펩토닉 메디컬 에이비 | 생물막 분해 또는 생물막 형성 방지에 사용하기 위한 조성물 |
| EP4351506A4 (en) * | 2021-06-11 | 2025-04-23 | Ankh Life Sciences Limited | Lipid crystalline compositions with enhanced stability for topical delivery of active agent combinations |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| SE454397B (sv) * | 1985-12-20 | 1988-05-02 | Biogram Ab | Stabiliserad vattenbaserad antimikrobiell veteperoxidkomposition, forfarande for framstellning derav samt anvendning derav som antimikrobiell spendoppningskomposition for mjolkproducerande djur |
| JPH06279228A (ja) | 1993-03-30 | 1994-10-04 | Kao Corp | 発泡性組成物 |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| JPH07197083A (ja) | 1993-12-28 | 1995-08-01 | Kao Corp | 洗浄剤組成物 |
| US5741525A (en) | 1995-10-24 | 1998-04-21 | Marshall University Research Corporation | Vaginal pharmaceutical hydrogen peroxide composition |
| US5778886A (en) * | 1996-02-27 | 1998-07-14 | Shihata; Alfred | Vaginal compositions combining a spermicidal agent and a peroxygen compound |
| US6156294A (en) | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US20020031556A1 (en) * | 2000-07-21 | 2002-03-14 | Lindahl Ake R. | Stabilized hydrogen peroxide composition and method of making a stabilized hydrogen peroxide composition |
| US7709026B2 (en) | 2001-10-29 | 2010-05-04 | Columbia Laboratories, Inc. | Low concentration of peroxide for treating or preventing vaginal infections |
| US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
| EP2289512B8 (en) | 2003-01-24 | 2017-08-02 | Stiefel Research Australia Pty Ltd | Pharmaceutical foam |
| US8193244B1 (en) | 2008-05-29 | 2012-06-05 | Nevada Naturals, Inc. | Antimicrobial agents |
| US20040197270A1 (en) * | 2003-04-01 | 2004-10-07 | Mundschenk David D. | Topical formulations and delivery systems |
| JP2007503428A (ja) * | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー． | 浸透性医薬発泡剤 |
| US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| ZA200507019B (en) | 2004-04-28 | 2008-02-27 | Foamix Ltd | Body cavity foams |
| TW200719884A (en) | 2005-03-10 | 2007-06-01 | 3M Innovative Properties Co | Methods of treating ear infections |
| US20070299043A1 (en) * | 2005-10-03 | 2007-12-27 | Hunter William L | Anti-scarring drug combinations and use thereof |
| WO2007079069A1 (en) * | 2005-12-29 | 2007-07-12 | 3M Innovative Properties Company | Foamable dental compositions and methods |
| WO2008075207A2 (en) | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
| WO2008110872A2 (en) * | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
| SI2142186T1 (sl) * | 2007-03-30 | 2014-08-29 | Laccure Ab | Uporaba oligomerov mlečne kisline pri zdravljenju ginekoloških infekcij |
| PL2020221T3 (pl) * | 2007-06-19 | 2012-07-31 | Neubourg Skin Care Gmbh & Co Kg | Kremy DMS (Derma Membrane Structure) w postaci pianki |
| US20090239775A1 (en) * | 2008-03-19 | 2009-09-24 | Collins Gary L | Ophthalmic solutions displaying improved efficacy |
| CA2776474C (en) | 2009-10-02 | 2021-01-12 | Foamix Ltd. | Topical tetracycline compositions |
| US8414868B2 (en) * | 2010-02-04 | 2013-04-09 | Ultradent Products, Inc. | In situ foamable dental bleaching compositions and methods, systems and kits for bleaching teeth using such compositions |
| CA2910114A1 (en) * | 2013-04-26 | 2014-10-30 | Bioglan Ab | Composition for use in reducing scab formation and promoting healing |
| US9895311B2 (en) * | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
-
2015
- 2015-09-24 US US14/864,083 patent/US9895311B2/en active Active
- 2015-09-25 EP EP23156021.0A patent/EP4218803A3/en not_active Withdrawn
- 2015-09-25 PL PL15843723.6T patent/PL3197431T3/pl unknown
- 2015-09-25 RU RU2017112055A patent/RU2710019C2/ru active
- 2015-09-25 WO PCT/SE2015/051011 patent/WO2016048230A1/en not_active Ceased
- 2015-09-25 EP EP15843723.6A patent/EP3197431B1/en active Active
- 2015-09-25 CA CA2959717A patent/CA2959717C/en active Active
- 2015-09-25 FI FIEP15843723.6T patent/FI3197431T3/fi active
- 2015-09-25 AU AU2015322112A patent/AU2015322112B2/en not_active Ceased
- 2015-09-25 PT PT158437236T patent/PT3197431T/pt unknown
- 2015-09-25 DK DK15843723.6T patent/DK3197431T3/da active
- 2015-09-25 BR BR112017006154-6A patent/BR112017006154B1/pt not_active IP Right Cessation
- 2015-09-25 CN CN201580051590.3A patent/CN106687109B/zh not_active Expired - Fee Related
- 2015-09-25 KR KR1020177010958A patent/KR102569954B1/ko active Active
- 2015-09-25 HU HUE15843723A patent/HUE062224T2/hu unknown
- 2015-09-25 JP JP2017516659A patent/JP6659674B2/ja not_active Expired - Fee Related
- 2015-09-25 ES ES15843723T patent/ES2946510T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3197431A1 (en) | 2017-08-02 |
| EP4218803A3 (en) | 2023-11-01 |
| WO2016048230A1 (en) | 2016-03-31 |
| BR112017006154B1 (pt) | 2024-01-23 |
| US9895311B2 (en) | 2018-02-20 |
| CA2959717A1 (en) | 2016-03-31 |
| RU2710019C2 (ru) | 2019-12-24 |
| RU2017112055A3 (enExample) | 2019-03-25 |
| AU2015322112A1 (en) | 2017-03-30 |
| EP3197431B1 (en) | 2023-03-08 |
| JP2017529377A (ja) | 2017-10-05 |
| BR112017006154A2 (en) | 2018-02-06 |
| PT3197431T (pt) | 2023-05-10 |
| RU2017112055A (ru) | 2018-10-25 |
| FI3197431T3 (fi) | 2023-05-11 |
| JP6659674B2 (ja) | 2020-03-04 |
| KR102569954B1 (ko) | 2023-08-22 |
| KR20170059000A (ko) | 2017-05-29 |
| HUE062224T2 (hu) | 2023-10-28 |
| CN106687109B (zh) | 2020-10-23 |
| AU2015322112B2 (en) | 2020-10-22 |
| DK3197431T3 (da) | 2023-06-06 |
| CN106687109A (zh) | 2017-05-17 |
| US20160089333A1 (en) | 2016-03-31 |
| EP3197431A4 (en) | 2018-04-04 |
| CA2959717C (en) | 2022-10-18 |
| EP4218803A2 (en) | 2023-08-02 |
| PL3197431T3 (pl) | 2023-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2946510T3 (es) | Composiciones formadoras de espuma y métodos para suministrar un agente activo a una cavidad corporal | |
| US20050095245A1 (en) | Pharmaceutical delivery system | |
| JP2013529636A (ja) | 胞子形成微生物の減少を増強するための組成物及び方法 | |
| ES2947949T3 (es) | Composiciones formadoras de espuma para administrar un activo a una cavidad corporal | |
| JP2017529377A5 (enExample) | ||
| ES2222225T3 (es) | Utilizacion de tosilcloramida(s) para producir medicamentos para el tratamiento de enfermedades de la piel y de la mucosa. | |
| CN102361630A (zh) | 制备低溶解度物质的混悬剂的方法 | |
| US20240082128A1 (en) | Composition for use in degradation of biofilm or prevention of biofilm formation | |
| OA18854A (en) | Foam-Forming Compositions and Methods for Delivering an Active Agent to a Body Cavity | |
| HK1242202B (en) | Foam-forming compositions and methods for delivering an active agent to a body cavity | |
| HK1242202A1 (en) | Foam-forming compositions and methods for delivering an active agent to a body cavity | |
| RU2773520C2 (ru) | Пенообразующие композиции для доставки активного агента в полость тела | |
| HK40017987A (en) | Foam-forming compositions for delivering an active to a body cavity | |
| HK40017987B (en) | Foam-forming compositions for delivering an active to a body cavity | |
| OA20623A (en) | Foam-forming compositions for delivering an active to a body cavity. |